SCHEMBL5649294

SCHEMBL5649294

CC(=O)c1cccc(OC(=O)N(C)c2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
NPC1 O15118 2/20 0.71
L3MBTL1 Q9Y468 4/20 0.61
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ALDH1A1 P00352 2/20 0.55
NPSR1 Q6W5P4 2/20 0.54
LMNA P02545 2/20 0.53
MAOB P27338 1/20 0.51
CYP1A2 P05177 1/20 0.50
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LIPE Q05469 3/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650591 0.83 SMN1; SMN2 (1.00) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL3877466 0.83 ACHE (0.59) RAB9AMEN1KMT2AALDH1A1NPSR1
SCHEMBL5648382 0.82 SMN1; SMN2 (0.63) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL3276088 0.82 RAB9A (0.75) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL5649351 0.82 RAB9A (0.57) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL5649347 0.82 SMN1; SMN2 (0.57) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL5647194 0.82 MEN1 (0.73) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL11436905 0.79 RAB9A (0.51) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL7804671 0.78 RAB9A (0.57) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1
SCHEMBL10344567 0.78 BCHE (0.60) RAB9ASMN1; SMN2NPC1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN claimed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL RAB9A 2926/4885SMN1; SMN2 4233/4885NPC1 814/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL RAB9A 3386/4885SMN1; SMN2 4133/4885NPC1 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.